Tags

Type your tag names separated by a space and hit enter

Diagnosing prodromal Alzheimer's disease: role of CSF biochemical markers.
Mech Ageing Dev 2006; 127(2):129-32MA

Abstract

Mild cognitive impairment (MCI) is an aetiologically heterogeneous syndrome. A correct prediction of MCI conversion to Alzheimer's disease (AD) represents a primary goal in routine clinical practice. Since the presence of pathological levels in >or=2 cerebrospinal fluid (CSF) biomarkers; amyloid protein (Abeta42), total tau (h-tau) and phospho-tau (p-tau) seems to reliably identifying MCI subjects converting to AD, we report our experience in a routine clinical setting. In the period from January 2001 to June 2003, 273 consecutive patients referred to our Memory Clinic for diagnostic assessment of cognitive impairment. Of them, 180 underwent a complete diagnostic evaluation including CSF dosage of fragment 1-42 of amyloid protein, total tau and phospho-tau (ELISA Method, Innogenetics, Gent, Belgium), after vascular or other secondary causes of dementia could be excluded. At baseline, 38% of the MCI subjects (20/55) showed pathological levels in >or=2 CSF biomarkers. After 1 year, 11 MCI patients converted to dementia, 33 remained stable, 11 showed a further progression of cognitive impairment still not fulfilling the diagnostic criteria for dementia. Of the 11 converters, 10 showed >or=2 pathological values CSF biomarkers and in all of them, p-tau was high. On the contrary, 29 out of 33 stable MCI (88%) showed no or one pathological CSF value. We confirm that pathological levels in >or=2 CSF biomarkers reliably predict MCI conversion to AD and correctly identify the stable form of MCI.

Authors+Show Affiliations

Section of Neurology, Department of Medical and Surgical Specialties and Public Health, University of Perugia, Ospedale Silvestrini, S. Andrea delle Fratte, 06156 Perugia, Italy. parnetti@unipg.itNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

16274728

Citation

Parnetti, Lucilla, et al. "Diagnosing Prodromal Alzheimer's Disease: Role of CSF Biochemical Markers." Mechanisms of Ageing and Development, vol. 127, no. 2, 2006, pp. 129-32.
Parnetti L, Lanari A, Silvestrelli G, et al. Diagnosing prodromal Alzheimer's disease: role of CSF biochemical markers. Mech Ageing Dev. 2006;127(2):129-32.
Parnetti, L., Lanari, A., Silvestrelli, G., Saggese, E., & Reboldi, P. (2006). Diagnosing prodromal Alzheimer's disease: role of CSF biochemical markers. Mechanisms of Ageing and Development, 127(2), pp. 129-32.
Parnetti L, et al. Diagnosing Prodromal Alzheimer's Disease: Role of CSF Biochemical Markers. Mech Ageing Dev. 2006;127(2):129-32. PubMed PMID: 16274728.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Diagnosing prodromal Alzheimer's disease: role of CSF biochemical markers. AU - Parnetti,Lucilla, AU - Lanari,Alessia, AU - Silvestrelli,Giorgio, AU - Saggese,Emanuele, AU - Reboldi,Paolo, Y1 - 2005/11/07/ PY - 2005/02/05/received PY - 2005/05/16/revised PY - 2005/09/15/accepted PY - 2005/11/9/pubmed PY - 2006/4/25/medline PY - 2005/11/9/entrez SP - 129 EP - 32 JF - Mechanisms of ageing and development JO - Mech. Ageing Dev. VL - 127 IS - 2 N2 - Mild cognitive impairment (MCI) is an aetiologically heterogeneous syndrome. A correct prediction of MCI conversion to Alzheimer's disease (AD) represents a primary goal in routine clinical practice. Since the presence of pathological levels in >or=2 cerebrospinal fluid (CSF) biomarkers; amyloid protein (Abeta42), total tau (h-tau) and phospho-tau (p-tau) seems to reliably identifying MCI subjects converting to AD, we report our experience in a routine clinical setting. In the period from January 2001 to June 2003, 273 consecutive patients referred to our Memory Clinic for diagnostic assessment of cognitive impairment. Of them, 180 underwent a complete diagnostic evaluation including CSF dosage of fragment 1-42 of amyloid protein, total tau and phospho-tau (ELISA Method, Innogenetics, Gent, Belgium), after vascular or other secondary causes of dementia could be excluded. At baseline, 38% of the MCI subjects (20/55) showed pathological levels in >or=2 CSF biomarkers. After 1 year, 11 MCI patients converted to dementia, 33 remained stable, 11 showed a further progression of cognitive impairment still not fulfilling the diagnostic criteria for dementia. Of the 11 converters, 10 showed >or=2 pathological values CSF biomarkers and in all of them, p-tau was high. On the contrary, 29 out of 33 stable MCI (88%) showed no or one pathological CSF value. We confirm that pathological levels in >or=2 CSF biomarkers reliably predict MCI conversion to AD and correctly identify the stable form of MCI. SN - 0047-6374 UR - https://www.unboundmedicine.com/medline/citation/16274728/Diagnosing_prodromal_Alzheimer's_disease:_role_of_CSF_biochemical_markers_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0047-6374(05)00240-X DB - PRIME DP - Unbound Medicine ER -